Cipla jumps on getting USFDA’s final approval for generic cancer drug
Cipla is currently trading at Rs. 1479.25, up by 62.95 points or 4.44% from its previous closing of Rs. 1416.30 on the BSE.
The scrip opened at Rs. 1465.30 and has touched a high and low of Rs. 1482.90 and Rs. 1456.95 respectively. So far 4830 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1702.00 on 09-Oct-2024 and a 52 week low of Rs. 1310.05 on 07-Apr-2025.
Last one week high and low of the scrip stood at Rs. 1499.25 and Rs. 1310.05 respectively. The current market cap of the company is Rs. 114382.81 crore.
The promoters holding in the company stood at 29.19%, while Institutions and Non-Institutions held 54.28% and 16.52% respectively.
Cipla has received final approval from the United States Food and Drug Administration (USFDA) for the Abbreviated New Drug Application (ANDA) submitted for Paclitaxel Protein-bound Particles for Injectable Suspension (albumin-bound), 100 mg/vial, Single-Dose Vial (‘Protein-bound Paclitaxel’) on April 10, 2025.
Cipla’s Protein-bound Paclitaxel is an AB-rated generic therapeutic equivalent version of Bristol Myers Squibb’s Abraxane for Injectable Suspension 100 mg/vial. Protein-bound Paclitaxel is indicated for the treatment of metastatic breast cancer, locally advanced or metastatic non-small cell lung cancer (NSCLC) and metastatic adenocarcinoma of the pancreas. The product is expected to be launched in H1 FY 2025-26 in the United States of America.
Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients.
